Kolahi Sousan, Mirtaheri Elham, Pourghasem Gargari Bahram, Khabbazi Alireza, Hajalilou Mehrzad, Asghari-Jafarabadi Mohammad, Mesgari Abbasi Mehran
1Connective Tissue Diseases Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
2Student Research Committee, Faculty of Nutrition and Food Sciences, Tabriz University of Medical Sciences, Tabriz, Iran.
Int J Vitam Nutr Res. 2019 Jul;89(1-2):13-21. doi: 10.1024/0300-9831/a000550. Epub 2019 Feb 21.
Rheumatoid arthritis (RA) is a chronic inflammatory disease in which oxidative stress could play a substantial pathological role. Alpha-lipoic acid (ALA) has been known as a "universal" and "ideal" antioxidant. The purpose of this study was to investigate the effects of oral administration of Alpha-lipoic acid (ALA) on lipid peroxidation and antioxidant biomarkers in Rheumatoid arthritis (RA) patients. The study was a randomized, double-blinded, placebo-controlled clinical trial. 70 RA patients were randomized 1:1 to two groups using blocked randomization method and received 1200 mg/day ALA or placebo for 8 weeks. Fasting blood samples were obtained before and after the intervention to analyze total antioxidant capacity (TAC), antioxidant enzymes [superoxide dismutase (SOD), glutathione peroxidase (GSH-Px) and arylesterase (ARE) activities] and malondialdehyde (MDA). We observed significant increase in serum TAC (0.11 mmol/L; p=0.033) and ARE (13.76 U/mL; p=0.046) and significant decline in MDA (-0.36 nmol/L; p=0.002), in ALA group. However, these changes in ALA-treated group were not statistically significant when compared with placebo-treated group (p > 0.05). Also, within- and between-group differences of whole blood SOD and GSH-Px were not statistically significant (p > 0.05). In conclusion, unexpectedly, ALA therapy did not affect the oxidative status of RA patients in the present clinical trial. It seems that more comprehensive clinical trials in RA patients are still warranted to clarify the effectiveness of ALA which has been known as a potent antioxidant.
类风湿性关节炎（RA）是一种慢性炎症性疾病，氧化应激在其中可能发挥重要的病理作用。α-硫辛酸（ALA）一直被认为是一种“通用”且“理想”的抗氧化剂。本研究的目的是调查口服α-硫辛酸（ALA）对类风湿性关节炎（RA）患者脂质过氧化和抗氧化生物标志物的影响。该研究是一项随机、双盲、安慰剂对照的临床试验。70例RA患者采用区组随机化方法1:1随机分为两组，接受1200毫克/天的ALA或安慰剂治疗8周。在干预前后采集空腹血样，以分析总抗氧化能力（TAC）、抗氧化酶[超氧化物歧化酶（SOD）、谷胱甘肽过氧化物酶（GSH-Px）和芳基酯酶（ARE）活性]以及丙二醛（MDA）。我们观察到，在ALA组中，血清TAC显著增加（0.11毫摩尔/升；p = 0.033），ARE显著增加（13.76单位/毫升；p = 0.046），MDA显著下降（-0.36纳摩尔/升；p = 0.002）。然而，与安慰剂治疗组相比，ALA治疗组的这些变化无统计学意义（p > 0.05）。此外，全血SOD和GSH-Px的组内和组间差异也无统计学意义（p > 0.05）。总之，出乎意料的是，在本临床试验中，ALA治疗并未影响RA患者的氧化状态。似乎仍有必要对RA患者进行更全面的临床试验，以阐明ALA作为一种有效抗氧化剂的有效性。
